Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as STACCATO® Loxapine for Inhalation
ADASUVE · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ADASUVE® | EXPERIMENTAL | oral inhalation using a single-use, hand-held, inhaler; dosage determined by the investigator according the participants weight |
| Name | Type | Description |
|---|---|---|
| ADASUVE® | DRUG | ADASUVE® 2.5, 5, or 10 mg |
Inclusion 1. Written informed consent is obtained from each patient's parent or legal guardian and written assent is obtained from each patient. 2. The patient is a boy or girl 10 through 17 years of age. 3. The patient is within the 2.5 to 97.5 percentile for body mass index (BMI) on the basis of ...
Top 10 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 4 | PHASE3 | Xanomeline and trospium chloride, Xanomeline/Trospium Chloride |
| AbbVie, Inc. | ABBV | 3 | PHASE3 | Cariprazine, ABBV-932, Icalcaprant |
| Xenon Pharmaceuticals Inc. | XENE | 2 | PHASE3 | Azetukalner |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Rapport Therapeutics, Inc. | RAPP | 1 | PHASE2 | RAP-219 |
| Neurocrine Biosciences, Inc. | NBIX | 1 | PHASE2 | NBI-1117568 |
| Alto Neuroscience, Inc. | ANRO | 1 | PHASE2 | ALTO-100 |
| LB Pharmaceuticals, Inc. | LBRX | 1 | PHASE2 | LB-102 |
| BioXcel Therapeutics, Inc. | BTAI | 1 | PHASE1 | BXCL501 |
| Alzamend Neuro, Inc. | ALZN | 1 | PHASE1 | AL001 |
ADASUVE is being studied in bipolar disorder, specifically in children and adolescents 10 through 17 years of age with any condition warranting chronic use of an antipsychotic medication. It is a small molecule in the psychiatry therapeutic area. The clinical program has focused on safety and pharmacokinetics in this pediatric population.
ADASUVE is developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. Teva is the sponsor of the clinical trial evaluating the drug in pediatric patients with bipolar disorder and other conditions requiring chronic antipsychotic treatment.
ADASUVE is in Phase 1 development. The single listed trial, NCT02184767, is a Phase 1 study that has been completed. The program has one total trial, with no active trials currently listed, and enrolled 30 participants.
ADASUVE has been evaluated in one completed clinical trial, NCT02184767, titled a study to assess the safety and pharmacokinetics of ADASUVE at doses of 2.5, 5, or 10 mg in children and adolescents 10 through 17 years of age with any condition warranting chronic use of an antipsychotic medication. It was conducted in the United States.
Yes, ADASUVE and ADASUVE® refer to the same drug. The registered trademark symbol is simply a notation of the brand name, and both forms appear in reference to the same product developed by Teva Pharmaceutical Industries Limited for bipolar disorder and related conditions requiring chronic antipsychotic treatment.
The ADASUVE trial NCT02184767 was an uncontrolled Phase 1 study, not randomized and not double blind. It enrolled 30 participants aged 10 through 17 years, included both sexes, did not use healthy volunteers, and assessed safety and pharmacokinetics at doses of 2.5, 5, or 10 mg.